Follow-The-Filings

Security · featured owners

COLL Collegium Pharmaceutical Inc.

Health Care COM Equity as of 2026 Q2 among managers we track

  • 1 Owner
  • Max 1.1%
  • $7M
  • 1 add

COLL (Collegium Pharmaceutical Inc.) is held in 1 featured 13F book as of 2026 Q2. Third Avenue Management is the largest tracked holder by portfolio weight (1.1%). Figures are as-filed 13F, not free float.

Who owns this now

Largest portfolio weights among featured holders · max 1.1% (Third Avenue Management) · not free-float ownership

  1. Third Avenue Management add 1.1%

holders

sorted by value · long equity only · current book 2026 Q2 · open a manager for their book

history
Third Avenue Management 2026 Q2 1.1% Add +17.7% 182,645 $7M history

1 current · options excluded

SEC filings

Recent issuer filings from EDGAR · 15 shown · open Filing / Doc on SEC.gov

Filed Form Detail Links
8-K 8.01 Filing Doc
8-K 2.02,7.01 Filing Doc
10-Q Filing Doc
8-K/A 9.01 Filing Doc
8-K 5.07 Filing Doc
8-K 2.01,5.02,7.01,9.01 Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
10-Q Filing Doc
8-K 5.02 Filing Doc
8-K 1.01,7.01,9.01 Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
10-K Filing Doc
8-K 7.01,9.01 Filing Doc
8-K 1.01,1.02,3.02,7.01,9.01 Filing Doc
10-Q Filing Doc

Insider forms

Form 3 / 4 / 5 from EDGAR · 14 rows shown

Filed Form Detail Links
4 Period Jun 8, 2026 Filing Doc
4 Period May 18, 2026 Filing Doc
4 Period May 14, 2026 · 7 forms Filing Doc
4 Period May 13, 2026 Filing Doc
4 Period May 11, 2026 Filing Doc
4 Period Mar 17, 2026 Filing Doc
4 Period Mar 18, 2026 Filing Doc
4 Period Mar 9, 2026 Filing Doc
4 Period Mar 3, 2026 Filing Doc
4 Period Feb 10, 2026 · 5 forms Filing Doc
4 Period Dec 8, 2025 Filing Doc
4 Period Dec 5, 2025 Filing Doc
4 Period Nov 12, 2025 · 2 forms Filing Doc
4 Period Nov 6, 2025 Filing Doc

Updated 5 days ago Source: SEC EDGAR submissions All on EDGAR

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue $566.77M $631.45M $780.57M
Gross profit $326.17M $377.34M $463.26M
Gross margin * 57.5% 59.8% 59.3%
Net income $48.16M $69.19M $62.87M
Net margin * 8.5% 11.0% 8.1%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $537.6M $482.26M $691.41M
Total non-current assets * $0.606B $1.18B $0.965B
Total assets $1.14B $1.66B $1.66B
Total current liabilities $457.92M $509.51M $440.03M
Total non-current liabilities * $489.96M $925.24M $915.13M
Total equity $195.43M $228.84M $301.68M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $274.75M $204.98M $329.32M
Cash from investing -$70.81M -$287.76M -$63.53M
Cash from financing -$140.18M -$60.6M -$110.24M
Net change in cash * $63.76M -$143.38M $155.55M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

ownership over time

filing count by report period · click a bar for that quarter’s holders